NO943653L - Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon - Google Patents

Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon

Info

Publication number
NO943653L
NO943653L NO943653A NO943653A NO943653L NO 943653 L NO943653 L NO 943653L NO 943653 A NO943653 A NO 943653A NO 943653 A NO943653 A NO 943653A NO 943653 L NO943653 L NO 943653L
Authority
NO
Norway
Prior art keywords
prevention
treatment
monoclonal antibodies
hiv
neutralizing monoclonal
Prior art date
Application number
NO943653A
Other languages
English (en)
Norwegian (no)
Other versions
NO943653D0 (no
Inventor
Emilio A Emini
Anthony J Conley
George E Mark
L Syd Johnson
David S Pfarr
Original Assignee
Merck & Co Inc
Medimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Medimmune Inc filed Critical Merck & Co Inc
Publication of NO943653D0 publication Critical patent/NO943653D0/no
Publication of NO943653L publication Critical patent/NO943653L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • C07K16/1045Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO943653A 1992-04-01 1994-09-30 Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon NO943653L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86170192A 1992-04-01 1992-04-01
PCT/US1993/002629 WO1993019785A1 (en) 1992-04-01 1993-03-23 Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection

Publications (2)

Publication Number Publication Date
NO943653D0 NO943653D0 (no) 1994-09-30
NO943653L true NO943653L (no) 1994-11-30

Family

ID=25336532

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943653A NO943653L (no) 1992-04-01 1994-09-30 Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon

Country Status (19)

Country Link
EP (1) EP0577243A3 (fi)
JP (1) JPH06217791A (fi)
KR (1) KR950700761A (fi)
CN (1) CN1081716A (fi)
AU (2) AU3928593A (fi)
BG (1) BG99074A (fi)
CA (1) CA2093099A1 (fi)
CZ (1) CZ239694A3 (fi)
FI (1) FI944561A0 (fi)
HU (1) HUT70461A (fi)
IL (1) IL105145A0 (fi)
MX (1) MX9301858A (fi)
NO (1) NO943653L (fi)
NZ (1) NZ251582A (fi)
RU (1) RU94045907A (fi)
SK (1) SK116294A3 (fi)
WO (1) WO1993019785A1 (fi)
YU (1) YU22693A (fi)
ZA (1) ZA932308B (fi)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69916306T2 (de) * 1998-10-30 2005-05-04 Novozymes A/S Niedrigallergene proteinvarianten
RU2221873C2 (ru) * 2001-04-24 2004-01-20 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
US7560529B2 (en) 2001-04-24 2009-07-14 FDS Pharma Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
US8332159B2 (en) 2003-02-20 2012-12-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for enhancing efficacy of preparation of monoclonal antibody
JP2010536885A (ja) * 2007-08-24 2010-12-02 ノバルティス アーゲー V3ループに改変を有するhivenvタンパク質
CN102272134B (zh) 2008-12-09 2013-10-16 吉里德科学公司 Toll样受体调节剂
US10421803B2 (en) 2014-01-31 2019-09-24 The Rockefeller University Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits
MX2017000026A (es) * 2014-07-11 2017-05-01 Gilead Sciences Inc Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
MX2017003284A (es) 2014-09-16 2017-06-28 Gilead Sciences Inc Formas solidas de modulador de receptor tipo toll.
WO2021227138A1 (zh) * 2020-05-09 2021-11-18 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒的单克隆抗体或其抗原结合部分

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853779T2 (de) * 1987-05-29 1995-09-07 Baylor College Medicine Hiv-1 neutralisierende monoklonale antikörper.
EP0311228A3 (en) * 1987-10-09 1990-05-02 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
WO1990015078A1 (en) * 1989-06-05 1990-12-13 Scott Charles F Jr HUMAN MONOCLONAL ANTIBODIES TO HIV-1MN gp 120
WO1991019797A1 (en) * 1990-06-15 1991-12-26 New York University Heterohybridomas producing human monoclonal antibodies to hiv-1
EP0624193A1 (en) * 1992-01-29 1994-11-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Aamp-1, a protein with local homologies to hiv-1 env and nef proteins

Also Published As

Publication number Publication date
ZA932308B (en) 1994-09-30
YU22693A (sh) 1997-01-08
EP0577243A3 (en) 1994-11-02
HU9402824D0 (en) 1994-11-28
MX9301858A (es) 1994-03-31
CN1081716A (zh) 1994-02-09
KR950700761A (ko) 1995-02-20
AU3563093A (en) 1993-10-07
HUT70461A (en) 1995-10-30
RU94045907A (ru) 1996-11-10
AU3928593A (en) 1993-11-08
SK116294A3 (en) 1996-11-06
NZ251582A (en) 1997-07-27
CZ239694A3 (en) 1995-07-12
FI944561A (fi) 1994-09-30
EP0577243A2 (en) 1994-01-05
FI944561A0 (fi) 1994-09-30
JPH06217791A (ja) 1994-08-09
NO943653D0 (no) 1994-09-30
IL105145A0 (en) 1993-07-08
WO1993019785A1 (en) 1993-10-14
AU658987B2 (en) 1995-05-04
CA2093099A1 (en) 1993-10-02
BG99074A (en) 1995-11-30

Similar Documents

Publication Publication Date Title
ATE330631T1 (de) Antikörperfragmente zur lokalen behandlung von augenerkrankungen
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
DK0626447T3 (da) Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen
PT712863E (pt) Anticorpos monoclonais humanizados e quimericos que reconhecem o receptor do factor de crescimento epidermico (egf-r); utilizacao diagnostica e terapetica
ATE373712T1 (de) Natürlicher menschlicher antikörper
DK0666868T4 (da) Anvendelse af anti-VEGF-antistoffer til behandling af cancer
PT699237E (pt) Fvs de cadeia anti-egfr e anticorpos anti-egfr
CA2310888A1 (en) Monoclonal human natural antibodies
NO943653L (no) Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
DK0546076T3 (da) Anvendelse af anti-ICAM antistoffer til fremstilling af et lægemiddel til behandling af endotoksiskshock
FI20040696A (fi) Immunoglobuliini-isotyyppiä vastaan suunnatut uudelleenmuotoillut monoklonaaliset vasta-aineet
SE9201281D0 (sv) New human monoclonal antibodies, and a method for preparation thereof
DE69941051D1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier
ES2000615A6 (es) Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3"
KR890016165A (ko) 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
NO984851L (no) DHEA kombinasjonsterapi
NO924803L (no) Tumor-relatert monoklonalt antistoff 88bv59

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application